“Not in Our Name” – African HIV Treatment Advocates React to Gilead’s Voluntary Licensing Agreement on Lenacapavir
4th October 2024 The announcement by Gilead that six generic manufacturers have been awarded voluntary licenses for the production of lenacapavir—a groundbreaking, twice-yearly injectable for